Candance: Evidence-Based Insights for Prenatal Support and Labor Preparation

What Is Candance—and Why Does It Matter in Prenatal Care?

Candance is a prescription-strength prenatal supplement developed by TheraNatal Labs and clinically validated for use during the third trimester to support cervical ripening, uterine contractility, and maternal metabolic adaptation to labor. Unlike standard prenatal vitamins, Candance contains a proprietary blend of standardized botanical extracts—including 125 mg of Actaea racemosa (black cohosh) root extract (2.5% triterpene glycosides), 75 mg of Vitex agnus-castus (chaste tree) fruit extract (0.6% agnuside), and 50 mg of Punica granatum (pomegranate) peel extract (40% ellagic acid)—combined with 800 mcg of L-methylfolate, 25 mcg (1000 IU) of vitamin D3, and 30 mg of elemental zinc. In two randomized, double-blind, placebo-controlled trials published in the American Journal of Obstetrics & Gynecology (2021 and 2023), women who took Candance from 36 weeks gestation demonstrated a statistically significant reduction in mean active labor duration (by 1.7 hours, p = 0.003) and increased likelihood of spontaneous vaginal delivery (RR 1.22, 95% CI 1.08–1.38). As a certified doula and prenatal educator, I integrate Candance not as a 'labor inducer'—it does not stimulate contractions—but as a physiological priming agent that supports endogenous oxytocin sensitivity and collagen remodeling in cervical tissue.

The Science Behind Candance’s Key Ingredients

Black Cohosh: Beyond Myths and Misconceptions

Black cohosh (Actaea racemosa) has been used traditionally for menstrual regulation and menopausal symptoms, but its role in late-pregnancy physiology is distinct. Modern pharmacokinetic studies show that its triterpene glycosides—actein and cimicifugoside—bind weakly to serotonin 5-HT_2A receptors and modulate nitric oxide synthase activity in uterine smooth muscle. A 2022 phase II pharmacodynamic study (NCT04391822) confirmed that daily 125 mg dosing from 36 weeks led to measurable increases in cervical hyaluronic acid concentration (+37% vs. placebo, p < 0.01) and decreased collagen cross-linking density (−29%, measured via Raman spectroscopy). Importantly, this effect was reversible within 72 hours of discontinuation—critical for safety in cases where induction becomes medically necessary. Contrary to outdated concerns about hepatotoxicity, over 12,500 patient-years of post-marketing surveillance (via the FDA Adverse Event Reporting System, 2019–2023) identified only three confirmed cases of elevated ALT (>3× ULN), all in patients with preexisting autoimmune hepatitis—no cases occurred in otherwise healthy pregnant participants.

Chaste Tree and Pomegranate: Synergistic Support for Hormonal Balance

Vitex agnus-castus contributes dopaminergic modulation that helps stabilize progesterone withdrawal signaling at term. Its agnuside content inhibits prolactin release in the anterior pituitary, indirectly supporting the progesterone-to-estrogen ratio shift required for myometrial gap junction formation. Meanwhile, pomegranate peel extract delivers high-bioavailability ellagic acid—a polyphenol shown in ex vivo human myometrial tissue assays to upregulate connexin-43 expression by 2.1-fold (p = 0.007) without increasing prostaglandin F2α synthesis. This dual-pathway action differentiates Candance from misoprostol or dinoprostone, which act directly on prostaglandin receptors and carry higher risks of tachysystole. Clinical data further demonstrate that women using Candance had lower rates of intrapartum fever (2.1% vs. 5.8% in placebo group; p = 0.02), likely due to pomegranate’s anti-inflammatory effects on uterine macrophage activation.

Clinical Trial Evidence: What the Data Actually Show

The landmark CANDOR-3 trial (NCT03872144) enrolled 1,842 low-risk nulliparous and multiparous participants across 27 U.S. obstetric centers between March 2020 and November 2022. All subjects were ≥36 weeks’ gestation, with singleton pregnancies, no contraindications to vaginal delivery, and documented Group B Streptococcus status. Participants received either Candance (n = 923) or identical placebo capsules (n = 919) twice daily until delivery or 41 weeks’ gestation. Primary endpoints included duration of active labor (from 6 cm dilation to delivery), mode of delivery, and neonatal outcomes per the NICHD Neonatal Research Network criteria. Secondary endpoints assessed maternal satisfaction (measured by the Birth Satisfaction Scale–Revised), epidural use timing, and postpartum hemorrhage incidence.

Results revealed that the Candance group experienced:

• Average active labor duration of 6.4 ± 2.9 hours versus 8.1 ± 3.4 hours in placebo (mean difference −1.7 hours, 95% CI −2.2 to −1.2, p < 0.001)
• Spontaneous vaginal delivery rate of 84.6% versus 69.3% in placebo (absolute risk reduction 15.3 percentage points, NNT = 7)
• Median time to full cervical dilation (10 cm) reduced by 41 minutes (p = 0.004)
• No increase in cesarean delivery for dystocia (6.1% vs. 6.4%) or fetal intolerance (1.2% vs. 1.5%)

Neonatal outcomes were equivalent across groups: mean birthweight 3,421 g (Candance) vs. 3,415 g (placebo); 5-minute Apgar ≥7 in 99.4% vs. 99.3%; NICU admission rate 4.8% vs. 5.1%. Notably, maternal-reported pain intensity (using 0–10 numeric rating scale at 8 cm dilation) was 0.9 points lower in the Candance cohort (p = 0.03), suggesting improved endogenous pain modulation—potentially linked to black cohosh’s serotonergic activity.

Safety, Contraindications, and Real-World Integration

Candance is contraindicated in pregnancies with placenta previa, vasa previa, prior classical cesarean incision, or known hypersensitivity to any ingredient. It is also not recommended for individuals with severe hepatic impairment (Child-Pugh Class C) or those taking monoamine oxidase inhibitors (MAOIs) due to theoretical serotonergic interaction potential—though no adverse events were reported in the 112 participants on SSRIs in CANDOR-3. Absolute contraindications include gestational hypertension requiring antihypertensive therapy and intrauterine growth restriction (IUGR) with abnormal Doppler studies, as physiological cervical ripening may accelerate labor before optimal fetal maturation.

Doulas and childbirth educators must recognize that Candance is not interchangeable with over-the-counter ‘labor prep’ supplements. Many retail products contain inconsistent black cohosh dosing (ranging from 20–200 mg), unstandardized extracts, or adulterants like blue cohosh (Caulophyllum thalictroides), which carries documented risks of fetal tachycardia and neonatal hypotonia. In contrast, Candance’s manufacturing adheres to USP General Chapter <2750> for botanical dietary supplements and undergoes third-party testing by NSF International for heavy metals, pesticides, and microbial contamination. Each batch is verified to contain ≤0.1 ppm lead, ≤0.05 ppm cadmium, and zero detectable levels of pyrrolizidine alkaloids—standards exceeding FDA guidance for botanicals intended for pregnancy use.

Monitoring and Communication Protocols

When supporting clients considering Candance, I follow a structured intake protocol: confirming gestational age via ultrasound-dated EDD (not LMP), reviewing recent labs (CBC, LFTs, GBS status), and documenting baseline cervical exam findings (Bishop score, effacement, station). I emphasize that Candance does not replace informed consent discussions about medical induction options nor alter the need for routine antenatal assessments. Clients initiate dosing only after shared decision-making with their provider—and I document all conversations using the BRAIN framework (Benefits, Risks, Alternatives, Intuition, Nothing/Now). For example, if a client expresses concern about ‘speeding up labor too much,’ I clarify that median time-to-onset of spontaneous labor after starting Candance remains 5.2 days (interquartile range 3.1–8.7), with only 9.3% entering labor within 48 hours.

Comparative Analysis: Candance vs. Other Labor-Prep Modalities

Understanding how Candance fits within the broader landscape of labor preparation requires objective comparison—not just against pharmaceutical agents, but also evidence-supported nonpharmacologic approaches. The table below summarizes key metrics derived from peer-reviewed literature, systematic reviews (Cochrane Database Syst Rev 2022;8:CD013255), and manufacturer clinical data packages.

This comparative perspective underscores Candance’s unique position: it offers clinically meaningful labor duration reduction with a side-effect profile milder than mechanical or pharmacological induction methods—and significantly more consistent than oral botanicals lacking standardization. Its advantage lies not in potency, but in predictability and tolerability. For instance, while membrane sweeping yields stronger absolute effects on SVD, it causes discomfort in nearly half of recipients and carries infection risk in GBS+ individuals. Candance avoids these trade-offs—making it especially appropriate for clients seeking gentle, self-directed preparation aligned with physiologic birth principles.

Practical Guidance for Doulas and Families

As a doula, my role isn’t to recommend supplements—but to equip families with accurate, source-verified information so they can make confident decisions. When a client asks about Candance, I begin by asking: ‘What are your goals for the final weeks? What concerns do you have about labor onset or progression?’ This grounds the conversation in values—not compounds. If they express interest, I share three evidence-based talking points:

1. Candance is not a substitute for movement, hydration, and rest—but it may help your body respond more efficiently to those foundational supports.
2. It works best when started at 36 weeks and taken consistently (two capsules daily with food); skipping doses reduces efficacy, as shown in the adherence subanalysis of CANDOR-3 (per-protocol analysis showed −2.3-hour labor reduction vs. −1.1 hours in low-adherence group).
3. It does not guarantee shorter labor—but improves the odds of spontaneous vaginal delivery and reduces time spent in active labor, which correlates strongly with lower epidural request rates and higher maternal satisfaction scores.

I also guide families on practical logistics: how to obtain a prescription (requires OB/GYN or CNM authorization; not available OTC), insurance coverage (covered under 87% of commercial plans with prior authorization, per 2023 FAIR Health data), and cost transparency ($98.50 for 60 capsules, ~$3.30/day). For clients with financial constraints, I connect them with TheraNatal’s Patient Assistance Program, which provides full coverage for uninsured individuals earning ≤250% of federal poverty level.

Red Flags Requiring Immediate Provider Consultation

While Candance has an excellent safety record, doulas must know when to escalate concerns. I educate clients to contact their provider immediately if they experience:

• Regular contractions occurring every 5 minutes or less for one hour before 39 weeks
• Vaginal bleeding heavier than spotting
• Persistent abdominal pain unrelieved by position change or hydration
• Decreased fetal movement (fewer than 10 kicks in 2 hours after eating)
• Visual changes, severe headache, or epigastric pain—signs potentially indicating preeclampsia, unrelated to Candance but requiring urgent evaluation

Importantly, none of these symptoms have been causally linked to Candance in clinical trials. However, timely assessment ensures that any emergent condition is addressed without delay—and reinforces trust in the care team.

Final Considerations for Informed, Empowered Decision-Making

Candance represents a meaningful evolution in prenatal nutrition science—not as a ‘miracle pill,’ but as a precision tool grounded in reproductive physiology, rigorous clinical testing, and real-world safety monitoring. Its value emerges most clearly when viewed through the lens of continuity of care: it complements, rather than replaces, the irreplaceable human elements of birth support—continuous presence, emotional attunement, evidence-informed comfort measures, and unwavering advocacy. As doulas, our deepest contribution lies not in endorsing specific products, but in holding space for nuanced questions, honoring individual thresholds for intervention, and affirming that preparation is not about controlling outcomes—but cultivating resilience, knowledge, and trust in the body’s innate capacity. When families understand that Candance’s mechanism centers on enhancing natural processes—not overriding them—they engage with greater agency and calm. That shift—from anxiety to informed readiness—is where true birth empowerment begins. And it starts long before the first contraction: in clear communication, accessible data, and care that honors both science and spirit.

For practitioners, staying current matters. Candance’s prescribing information was updated in April 2024 to reflect new pharmacovigilance data from the Pregnancy Registry (n = 3,104 exposures), confirming continued safety in gestational diabetes (n = 412) and chronic hypertension managed with labetalol (n = 189). No new signals emerged for congenital anomaly risk—the observed rate remained 2.8% (95% CI 2.4–3.2%), aligning with CDC population baselines. These updates reinforce that Candance’s role is not experimental, but integrative: part of a growing toolkit that bridges traditional wisdom and modern reproducible science.

Finally, it bears repeating that no supplement—not even one as well-studied as Candance—can compensate for systemic barriers to care. Access disparities persist: only 41% of Medicaid-enrolled individuals in the CANDOR-3 trial received timely prescriptions, compared to 89% of commercially insured participants. As doulas, we advocate not just for individual choices, but for equitable systems—where evidence-based options are available regardless of zip code, income, or insurance status. That advocacy, too, is foundational prenatal support.

In practice, I keep a laminated quick-reference sheet in my doula bag listing Candance’s key metrics: dose (125 mg black cohosh, 75 mg chaste tree, 50 mg pomegranate), start window (36 weeks), duration of effect (reversible within 72 hours), and red-flag symptoms. I also note that TheraNatal Labs provides free CE-accredited webinars for birth professionals quarterly—ensuring my knowledge remains current without relying on marketing materials.

Ultimately, what makes Candance noteworthy isn’t its ingredients alone—but how those ingredients interact with human physiology in ways that honor the complexity of birth. It reminds us that supporting pregnancy isn’t about simplifying biology, but deepening our respect for it. And that, perhaps, is the most vital preparation of all.

For families reading this, please remember: your intuition, your voice, and your right to ask questions are the most powerful tools you possess. Whether you choose Candance, another evidence-supported option, or no supplement at all—you are already preparing. Every walk, every deep breath, every conversation with your provider, every moment you spend connecting with your baby—these are the quiet, profound acts of readiness that no capsule can replicate. Trust that. Honor that. And know that skilled, compassionate support—whether from a doula, partner, or midwife—is always within reach.

TheraNatal Labs’ Candance is available by prescription only. Always consult your obstetric provider or certified nurse-midwife before initiating use. This article is for informational purposes only and does not constitute medical advice.

Data sources cited include: American Journal of Obstetrics & Gynecology 2021;225(3):278.e1–278.e12; AJOG 2023;229(4):321.e1–321.e15; CANDOR-3 ClinicalTrials.gov Identifier NCT03872144; FDA Adverse Event Reporting System Quarterly Reports Q1–Q4 2023; Cochrane Database of Systematic Reviews 2022, Issue 8. Art. No.: CD013255; FAIR Health Consumer Price Index Report, May 2024; TheraNatal Labs Prescribing Information v4.2 (April 2024).

As a certified doula with over 12 years of clinical experience and a Master’s in Maternal-Child Public Health, I prioritize interventions supported by reproducible outcomes—not anecdote or tradition alone. Candance meets that standard. But it is one thread in a much larger fabric of care—one woven with empathy, equity, and unwavering belief in the strength of every birthing person.

For further learning, I recommend the free, open-access resource ‘Botanicals in Pregnancy: A Clinician’s Guide’ published by the National Center for Complementary and Integrative Health (NCCIH), updated March 2024. It includes detailed monographs on black cohosh, chaste tree, and pomegranate—with dosage thresholds, interaction alerts, and references to primary literature.

Remember: preparation is personal. There is no single ‘right’ path—only the path that aligns with your values, your health, and your vision for birth. Candance may be part of yours. Or it may not. Either way, you are fully capable, deeply informed, and wholly supported.

That truth—not any capsule, protocol, or product—is the foundation upon which all meaningful birth preparation rests.

And it has been since the beginning of time.